After the initial technology validation study (27), the commercially available version of the anti-dsDNA-NcX ELISA was rarely investigated in clinical studies and most of its limited available published data was collected in China (41) and Thailand (42) and solely considered SLE patients of Asian ethnicity. This evidence concerns the gene TLX2 and systemic lupus erythematosus.